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JOURNAL OF HEPATOLOGYReply to: ‘‘Low free T3 levels are related to early mortality in patients
with decompensated cirrhosis and acute-on chronic liver failure’’To the Editor:
We would like to thank Agiasotelli et al. for taking a keen interest
in our recently published manuscript where we showed that
serum ferritin is a predictor of early mortality in patients with
decompensated cirrhosis [1]. Agiasotelli and colleagues demon-
strate that low T3 levels in patients with ACLF are associated with
an increased mortality. We would like to clarify that our patient
population was comprised of decompensated cirrhosis and not
ACLF patients. Further, we did not use the CLIF deﬁnition for
the diagnosis of ACLF [2,3].
We have looked into our cohort of patients with decompen-
sated cirrhosis (n = 318, 257 males) and patients with ACLF
(n = 148, 109 males), deﬁned according to the APASL criteria [2]
for abnormalities in thyroid function and their relationship to
predictors of mortality [1]. Median (IQR) free T3, free T4, and TSH
concentration were 2.3 (1.98–2.69) pg/ml, 1.04 (0.9–1.23) ng/L,
and 2.47 (1.28–4.27) lIU/ml, respectively in the decompensated
cirrhotic group. A signiﬁcant inverse correlation of T3 was noted
with predictors of early mortality i.e. the MELD (p = 0.0004,
0.36) and CTP score (p <0.00001, 0.43), hepatic encephalopa-
thy (p <0.0001, 0.46) and leucocyte counts (p = 0.002, 30).
Interestingly, low T3 levels also correlated with an increase in fer-
ritin (p = 0.007, 0.27). Similar to the observation by Agiasotelli
et al., low T3 was associated with decreased survival (log rank
p = 0.0003), whichwas not observed for T4 (p = 0.5) and TSH levels
(p = 0.6) (Fig. 1 A–C). On multivariate analysis, however, low T3
was not a signiﬁcant predictor of mortality in our cohort.
On the contrary, median (IQR) free T3, free T4, and TSH
concentration in patients with ACLF [2] were much lower as com-
pared to patients with decompensated cirrhosis i.e. 1.9 (1.6–2.2;
p <0.0001) pg/ml, 0.96 (0.73–1.12; p = 0.001) ng/L, and 2.1
(0.65–3.5; p = 0.01) lIU/ml, respectively. Low free T3 was noted
in 89% vs. 64% (p <0.0001), low T4 in 16% vs. 4% (p <0.0001) and
low TSH was noted in 18% vs. 3.5% (p <0.0001) of patients with
ACLF, as compared to patients with decompensated cirrhosis,
respectively. Interestingly, serum ferritin showed an inverse cor-
relation with both free T3 (r 0.18, p = 0.012) and TSH (r 0.234,
p = 0.03). Also, in these patients, a signiﬁcantly lower survival
was noted with low T3 (log rank p = 0.005), low T4 (p = 0.014)
as well as low TSH (p = 0.001) (Fig. 1D–F). This could be possible
because within the ﬁrst few hours of the critical illness, T3 con-
centrations decrease due to decreased peripheral deiodination,
while T4 and TSH concentrations may increase or remain normal.
However, if the illness becomes more protracted or severe, a
decrease in the concentration of T3, T4, and TSH is caused by a
decrease in TRH-release from the hypothalamus [4]. Our patients
with ACLF, diagnosed as per APASL deﬁnition, have characteristi-
cally an acute liver failure–like presentation (not just acute
decompensation) on a background of underlying chronic liver
disease with a sudden and massive loss of functional hepatocytes
and activation of the systemic inﬂammatory response syndrome
that probably puts extra stress on the thyroid [2]. In our cohort,
we also found patients with hepatorenal syndrome (HRS) with
signiﬁcantly lower free T3 as compared to those with no HRS
(2.19 ± 0.47 vs. 2.42 ± 0.62; p = 0.04). This is because the 50-mon-
odeiodinases, which produce T3, the biologically active hormone,
are also present in the kidney apart from the liver. Thus, our data
suggest that low T3 levels are frequent in patients with advanced
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Fig. 1. Survival probability of patients. Survival probability of patients with low FT3 (<2.5 pg/ml), FT4 (<0.58 ng/L), and TSH (<0.3 lIU/ml) vs. normal FT3 (2.5–3.9 pg/ml),
FT4 (0.58–1.64 ng/L), and TSH (0.3–5.6 lIU/ml) in decompensated cirrhosis (A–C) and ACLF (D–F).
Letters to the Editorliver disease and correlate with markers of disease severity and
outcome, but these abnormalities are more severe in patients
with ACLF [2]. However, it remains elusive whether these abnor-
malities occur as a protective adaptation or as a maladaptive
response to the systemic stress. Also, many confounders like star-
vation, catecholamines, drugs like corticosteroids, furosemide,
beta-blockers and others can also contribute to low free T3
concentration, which will need careful evaluation in future stud-
ies. It is also not known whether restoration of these alterations
with thyroid hormones could contribute to the recovery of any
physiological or metabolic parameters of such critically ill
patients with liver disease.
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